{"filing":{"accession_number":"0001493152-26-043844","cik":"0001506983","ticker":"GCTK","company_name":"Glucotrack, Inc.","form":"8-K","filing_date":"2026-09-23","report_date":"2026-09-23","primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1506983/000149315226043844/form8-k.htm"},"events":[{"id":34526,"run_id":31770,"accession_number":"0001493152-26-043844","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"summary":"The filing discloses a strategic corporate update following the completion of a business combination on July 14, 2026, outlining the company's post-merger structure, clinical development priorities (LT-100 program), and expansion of the ai² platform. While the merger itself was a material M\u0026A event, this 8-K Item 7.01 disclosure focuses on operational strategy and clinical development priorities rather than the M\u0026A transaction itself. The update describes organizational restructuring (Glucotrack Technologies as subsidiary, Lōkahi Therapeutics as parent focus), clinical protocol submission for LT-100, and platform expansion initiatives—all operational and strategic in nature.","company_name":"Glucotrack, Inc.","ticker":"GCTK","filing_date":"2026-09-23","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":38273,"accession_number":"0001493152-26-043844","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"The filing discloses a strategic corporate update following the completion of a business combination on July 14, 2026, outlining the company's post-merger structure, clinical development priorities (LT-100 program), and expansion of the ai² platform. While the merger itself was a material M\u0026A event, this 8-K Item 7.01 disclosure focuses on operational strategy and clinical development priorities rather than the M\u0026A transaction itself. The update describes organizational restructuring (Glucotrack Technologies as subsidiary, Lōkahi Therapeutics as parent focus), clinical protocol submission for LT-100, and platform expansion initiatives—all operational and strategic in nature.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-23T13:24:47.484945+00:00","company_name":"Glucotrack, Inc.","ticker":"GCTK","filing_date":"2026-09-23"}]}